BV-ICE

Phase I/II feasibility study of Brentuximab Vedotin in refractory / relapsed Hodgkin lymphoma patients who are treated by chemotherapy (ICE) in second line and eligible for autologous transplantation

Publications 2022

Lysa 2022_LYSA_Final results of brentuximab vedotin combined with ifosfamide-carboplatin-etoposide in first refractory/relapsed Hodgkin lymphoma: a lymphoma study association phase I/II study

Aspasia Stamatoullas, Hervé Ghesquières, Pierre Feugier, Marc André, Fabien Le Bras, Anne-Claire Gac, Cécile Borel, Thomas Gastinne, Philippe Quittet, Franck Morschhauser, Vincent Ribrag, Stephanie Guidez, Emmanuelle Nicolas-Virelizier, Alina Berriolo-Riedinger, Thierry Vander Borght, Véronique Edeline, Pauline Brice

doi: 10.1080/10428194.2022.2107204. Learn more

Oral presentation SFH 2020 | Dr Aspasia Stamatoullas

BV-ICE in failed Hodgkin’s lymphoma

Oral presentation	SFH 2020
Aspasia Stamatoullas	BV-ICE (brentuximab vedotin (BV) and ICE) in patients with relapsed or refractory Hodgkin’s lymphoma eligible for autologous transplantation: Phase II results

Poster	ISHL11, Cologne 2018
Aspasia Stamatoullas	PHASE I/II STUDY OF BRENTUXIMAB VEDOTIN IN FIRST REFRACTORY/RELAPSED CLASSICAL HODGKIN LYMPHOMA PATIENTS TREATED BY CHEMOTHERAPY (ICE) BEFORE AUTOLOGOUS TRANSPLANTATION.

Abstract Book	Lugano 2017
Aspasia Stamatoullas	Phase I/II study of Brentuximab Vedotin in refractory/relapsed Hodgkin lymphoma patients treated by chemotherapy (ICE) in second line before autologous transplantation